Related Experiment Video
Updated: Nov 10, 2025
Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors
Published on: January 20, 2023
[Expression and Clinical Significance of Heat Shock Protein 90 in Multiple Myeloma Patients]
Shun-Quan Wu1, Hui-Jun Chen1, Rong Zhan2
1Fujian Insitute of Hematology, Fujian Provincial Key Laboratory of Hematology, FUjian Medical University Union Hospital, Fuzhou 350001, Fujian Province, China.
Objective:
To investigate the expression of HSP90 in bone marrow samples of multiple myeloma (MM) patients and explore its clinical significance.
Methods:
Maxvision immunohistochemistry technique was used to detect the protein expression level of HSP90 76 MM patients and 29 normal healthy donors. The clinical characteristics of the patients were collected, and the correlation between the HSP90 expression and the clinical characteristics was analyzed.
Results:
The count of MM patients with positive HSP90 protein was significantly higher than that of normal healthy donor, and there were no significant correlation between HSP90 expression and age, sex, hemoglobin (Hb), creatinine (CREA), blood calcium, lactate dehydrogenase (LDH), bone marrow plasma cell proportion and MM subtypes (P>0.05), but HSP90 expression was correlated with β2-microglobulin (β2-MG) and ISS stage (P<0.05). The survival time was lower in MM patients with high expression HSP90 as compared with low expression HSP90 MM patients.
Conclusion:
HSP90 protein was over-expressed in MM patients, and was correlated with β2-microglobulin, ISS stage and OS of MM patients.
Insights
Heat shock protein 90 (HSP90) is overexpressed in multiple myeloma (MM) patients. High HSP90 expression correlates with advanced disease and poorer survival, indicating its potential as a prognostic biomarker in MM.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Multiple myeloma (MM) is a hematologic malignancy characterized by uncontrolled plasma cell proliferation.
- Heat shock protein 90 (HSP90) is a molecular chaperone involved in protein folding and stability, with implications in cancer progression.
- Understanding the role of HSP90 in MM pathogenesis is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the expression levels of HSP90 in bone marrow samples from MM patients.
- To explore the clinical significance and prognostic value of HSP90 expression in MM.
Main Methods:
- Maxvision immunohistochemistry was employed to detect HSP90 protein expression.
- The study included 76 MM patients and 29 healthy donors.
- Correlation analysis was performed between HSP90 expression and clinical characteristics, including survival data.
Main Results:
- HSP90 protein expression was significantly higher in MM patients compared to healthy controls.
- HSP90 expression showed a significant correlation with beta-2 microglobulin (β2-MG) and the International Staging System (ISS) stage.
- Elevated HSP90 expression was associated with shorter overall survival (OS) in MM patients.
Conclusions:
- HSP90 is overexpressed in multiple myeloma.
- HSP90 expression serves as a potential prognostic biomarker, correlating with key clinical indicators like β2-MG, ISS stage, and OS.
- These findings suggest HSP90 as a potential therapeutic target in MM.
